Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021

On November 12, 2021 Alligator Bioscience AB ("Alligator" or the "Company") reported new preclinical data highlighting the 4-1BB (CD137) antibody ATOR-1017 including an update on the ongoing phase 1 study (Press release, Alligator Bioscience, NOV 12, 2021, View Source [SID1234595323]). ATOR-1017, a promising candidate for immunotherapy with enormous potential for combination with other immunomodulatory antibodies, will be presented at the Society for Immunotherapy Cancer’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting & Pre-Conference Programs virtually on November 10th – 14th, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"By combining ATOR-1017 with antibodies blocking PD-1, tumor infiltrating T cells, in particular exhausted tumor specific T cells, can be more effectively activated and potentially increase the response rate in multiple types of cancer," stated Karin Enell Smith, PhD, MS, Principal Scientist at Alligator Bioscience. "The functional activation profile of ATOR-1017 is expected to minimize the risk of systemic immune activation and toxicity, by directing a potent immune response to immune cells in tumor tissue and tumor draining lymph nodes. This is supported by early data from the ongoing first-in human phase I study where ATOR-1017 has been shown to be safe and tolerable. These results support further clinical development of ATOR-1017 in combination with PD-1 blocking antibodies"

In addition, the poster includes data from the 360 mg cohort of the ongoing ATOR-1017 phase 1 study.

Title: ATOR-1017, a second generation 4-1BB antibody with potential to

enhance efficacy of PD-1 therapies

Presenter: Karin Enell Smith, PhD, MS

Virtual Meeting: E-Posters Session: Poster

The above poster presentations will be available online at www. View Source on Saturday, November 13, 2021.